BamSEC and AlphaSense Join Forces
Learn More

Argos Therapeutics Inc

Formerly OTC: ARGSQ
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.9
from 10-Q 5 pages Argos Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.8
from 10-Q 5 pages Argos Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.7
from 10-Q 5 pages Argos Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.6
from 10-Q 5 pages Release of Claims Agreement
12/34/56
EX-10.5
from 10-Q 5 pages Release of Claims Agreement
12/34/56
EX-10.4
from 10-Q 5 pages Release of Claims Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Retention Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Retention Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Retention Agreement
12/34/56
EX-10.4
from 10-Q 1 page By Email Re: Novated, Amended and Restated License Agreement Gentlemen
12/34/56
EX-10.51
from 10-K 2 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Third Amendment to License Agreement Between Argos Therapeutics, Inc. (Hereinafter “Argos”) - And - Lummy (Hong Kong) Co., Ltd. (Hereinafter “China Company”) This Amendment Is Made as of and Effective March 23th, 2018 (“Effective Date”), Contingent on the Full Execution of the Amended Second Stock Purchase Agreement Between China Company and Argos “Second Spa”)
12/34/56
EX-10.50
from 10-K 3 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Second Amendment to License Agreement Between Argos Therapeutics, Inc. (Hereinafter “Argos”) - And - Lummy (Hong Kong) Co., Ltd. (Hereinafter “China Company”) This Amendment Is Made as of and Effective _2017-10-18 (“Effective Date”), Contingent on the Full Execution of the Second Stock Purchase Agreement Between China Company and Argos “Second Spa”)
12/34/56
EX-10.49
from 10-K 16 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Double Asterisks Denote Omissions. Evaluation and Option Agreement for a Patent License
12/34/56
EX-10.2
from 8-K 18 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 37 pages Satisfaction and Release Agreement
12/34/56
EX-10.4
from 10-Q 1 page Material contract
12/34/56
EX-10.2
from 8-K 19 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 36 pages Satisfaction and Release Agreement
12/34/56
EX-10.1
from 8-K 11 pages Argos Therapeutics, Inc. 2014 Stock Incentive Plan
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56